CVM: רווח נקי למניה (EPS TTM) CEL-SCI Corporation

CEL-SCI Corporation revenues are based on finding a capital balance during the period of drug clinical trials. The TTM net income per share illustrates the quality of the business, where the metric value is -2.58. Growth prospects rely on the implementation of biologics in surgery and compliance with environmental standards for chemical waste processing in research centers.

CEL-SCI Corporation (CVM) operates in an intensive R&D mode without commercial sales, leading to a systemic reduction of capital. Fundamental net income per share TTM aggregates annual results, distributing the final financial outcome across the total volume of issuance. Negative dynamics for this metric reflect the burn rate of resources dedicated to immunotherapy development. This chart allows for an assessment of the business's loss rates. Investors perceive this trend as a risk of liquidity depletion.